What does SMETS PHARMA do?

SMETS PHARMA is a pharmacy in Lier. Private Limited, started on 1 January 1968, 1 establishment.

What is the address of SMETS PHARMA?

The registered office of SMETS PHARMA is located at Antwerpsesteenweg 36-38, 2500 Lier.

Is SMETS PHARMA still active?

Yes. According to the CBE (30 October 2026) SMETS PHARMA is active, legal situation “Normale toestand”, started on 1 January 1968.

Is SMETS PHARMA registered on Peppol?

Yes, SMETS PHARMA is registered on the Peppol network with ID 0208:0404059834.

What is the enterprise number of SMETS PHARMA?

The enterprise number of SMETS PHARMA is BE0404059834.

When was SMETS PHARMA founded?

SMETS PHARMA was founded on 1 January 1968.

Who are the directors of SMETS PHARMA?

According to the 2025 annual accounts, the directors of SMETS PHARMA are: Isaline Smets.

Is SMETS PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 January 1968; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SMETS PHARMA make in 2025?

SMETS PHARMA posted a profit after taxes of € 40,740 in financial year 2025.

What is the revenue of SMETS PHARMA?

As a small company, SMETS PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 273,890.

How much does an employee at SMETS PHARMA earn?

The average wage cost per full-time employee at SMETS PHARMA was € 81,400 in 2025: staff costs of € 179,052 for 2.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does SMETS PHARMA have?

According to the 2025 annual accounts, SMETS PHARMA has 2.2 full-time equivalents (FTE).

SMETS PHARMA (Private Limited) - Lier - BE0404059834

Dossier SMETS PHARMA, printed on 30 October 2026 from databakkes.be/en/0404059834/smets-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 64 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

SMETS PHARMA from Lier, company number BE0404059834, closed financial year 2025 with a result of € 40,740 after tax. For that financial year SMETS PHARMA recorded a gross margin of € 273,890 and equity of € 241,620. Compared with financial year 2024, the result moved from € 37,430 to € 40,740. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.

What it is worth Growing

€ 241,620

▲ 20% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 40,740

▲ 9% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 53,935

▼ 28% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 859 paid out

2 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

2.2

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 179,052

▼ 1% vs 2024

€ 81,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 2,615

▼ 42% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 57,225

▲ 6% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 26,754

▼ 6% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 202,756 Gross margin 2022: € 202,756 First fiscal year in the series	€ 262,474 Gross margin 2023: € 262,474 ▲ 29% vs 2022 (€ 202,756) Favourable step	€ 277,771 Gross margin 2024: € 277,771 ▲ 6% vs 2023 (€ 262,474) Favourable step	€ 273,890 Gross margin 2025: € 273,890 ▼ 1% vs 2024 (€ 277,771) Unfavourable step	▼ 1%
Profit after taxes	€ 5,426 Profit after taxes 2022: € 5,426 First fiscal year in the series	€ 27,607 Profit after taxes 2023: € 27,607 ▲ € 22,181 vs 2022 (€ 5,426) Favourable step	€ 37,430 Profit after taxes 2024: € 37,430 ▲ 36% vs 2023 (€ 27,607) Favourable step	€ 40,740 Profit after taxes 2025: € 40,740 ▲ 9% vs 2024 (€ 37,430) Favourable step	▲ 9%
Equity	€ 250,950 Equity 2022: € 250,950 First fiscal year in the series	€ 165,169 Equity 2023: € 165,169 ▼ 34% vs 2022 (€ 250,950) Unfavourable step	€ 201,739 Equity 2024: € 201,739 ▲ 22% vs 2023 (€ 165,169) Favourable step	€ 241,620 Equity 2025: € 241,620 ▲ 20% vs 2024 (€ 201,739) Favourable step	▲ 20%
Total debts	€ 96,992 Total debts 2022: € 96,992 First fiscal year in the series	€ 231,333 Total debts 2023: € 231,333 ▲ 139% vs 2022 (€ 96,992) Unfavourable step	€ 222,423 Total debts 2024: € 222,423 ▼ 4% vs 2023 (€ 231,333) Favourable step	€ 211,242 Total debts 2025: € 211,242 ▼ 5% vs 2024 (€ 222,423) Favourable step	▼ 5%
Cash	€ 62,133 Cash 2022: € 62,133 First fiscal year in the series	€ 71,722 Cash 2023: € 71,722 ▲ 15% vs 2022 (€ 62,133) Favourable step	€ 74,590 Cash 2024: € 74,590 ▲ 4% vs 2023 (€ 71,722) Favourable step	€ 53,935 Cash 2025: € 53,935 ▼ 28% vs 2024 (€ 74,590) Unfavourable step	▼ 28%
Land & buildings	€ 8,676 Land & buildings 2022: € 8,676 First fiscal year in the series	€ 8,676 Land & buildings 2023: € 8,676 Unchanged (€ 8,676) Unchanged	€ 10,367 Land & buildings 2024: € 10,367 ▲ 19% vs 2023 (€ 8,676) Unchanged	€ 41,075 Land & buildings 2025: € 41,075 ▲ 296% vs 2024 (€ 10,367) Unchanged	▲ 296%
Retained profit	€ 171,482 Retained profit 2022: € 171,482 First fiscal year in the series	€ 60,701 Retained profit 2023: € 60,701 ▼ 65% vs 2022 (€ 171,482) Unfavourable step	€ 97,271 Retained profit 2024: € 97,271 ▲ 60% vs 2023 (€ 60,701) Favourable step	€ 137,152 Retained profit 2025: € 137,152 ▲ 41% vs 2024 (€ 97,271) Favourable step	▲ 41%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 800 Dividend 2023: € 800 Unchanged (€ 0) Unchanged	€ 859 Dividend 2024: € 859 ▲ 7% vs 2023 (€ 800) Unchanged	€ 859 Dividend 2025: € 859 Unchanged (€ 859) Unchanged
Balance sheet total	€ 347,942 Balance sheet total 2022: € 347,942 First fiscal year in the series	€ 396,501 Balance sheet total 2023: € 396,501 ▲ 14% vs 2022 (€ 347,942) Unchanged	€ 424,162 Balance sheet total 2024: € 424,162 ▲ 7% vs 2023 (€ 396,501) Unchanged	€ 452,862 Balance sheet total 2025: € 452,862 ▲ 7% vs 2024 (€ 424,162) Unchanged	▲ 7%
Employees (FTE)	2.3 Employees (FTE) 2022: 2.3 First fiscal year in the series	2.3 Employees (FTE) 2023: 2.3 Unchanged (2.3) Unchanged	2.3 Employees (FTE) 2024: 2.3 Unchanged (2.3) Unchanged	2.2 Employees (FTE) 2025: 2.2 ▼ 0.1 vs 2024 (2.3) Unchanged	▼ 0.1

Key figures of SMETS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SMETS PHARMA?

What happened at SMETS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 7, 2026 New annual accounts for financial year 2025: profit of € 40,740 (▲ 9% vs 2024). Source: NBB ↗
2023 Isaline Smets became a director. NBB
Jan 1, 1968 Start of the company according to the CBE. KBO
Jan 1, 1960 New establishment in Lier. KBO

In short

From € 5,426 profit in 2022 to € 40,740 profit in 2025.

Paid € 40,494 in corporate taxes since 2022.

Best year ever: 2025, with € 40,740 profit.

On average € 124,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Isaline Smets

SMETS PHARMA

Behind SMETS PHARMA is Isaline Smets.

Directors

According to the 2025 annual accounts

Isaline Smets

Bestuurder

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Antwerpsesteenweg 36-38

2500 Lier

2.005.811.728

Antwerpsesteenweg 36 3

2500 Lier

Active since 1 January 1960

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0404.059.834

VAT number

BE 0404.059.834

Registered office

Antwerpsesteenweg 36-38, 2500 Lier

Names & denominations

SMETS PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

1 January 1968

Peppol

Active · Active since 24 Nov 2023

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Detailhandel in cosmetica en toiletartikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

SMETS PHARMA

Warning lights

Financials

What happened to SMETS PHARMA?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions